Paget-von Schrötter Syndrome: Primary Subclavian-axillary Vein Thrombosis in Sport Activities

2003 ◽  
Vol 13 (4) ◽  
pp. 269-271 ◽  
Author(s):  
M. A. Chaudhry ◽  
J. Hajarnavis
2020 ◽  
Vol 17 (3) ◽  
Author(s):  
Myung Gyu Song ◽  
Tae-Seok Seo ◽  
Woo Jin Yang

Background: The incidence of venous thrombosis based on access route after implantation of the totally implanted venous access port (TIVAP) is controversial. Symptomatic TIVAP-related venous thrombosis remains relatively rare. However, characteristics of symptomatic axillary vein thrombosis after TIVAP implantation via access of the axillary vein has not been reported. Objectives: In this historical cohort study, the incidence and characteristics of venous thrombosis associated with TIVAP via the axillary vein in cancer patients were evaluated. Patients and Methods: A total of 4,773 TIVAPs were placed via the axillary vein in patients with various types of cancer between May 2012 and July 2018. Eighteen patients experienced symptomatic venous thrombosis associated with TIVAPs. Radiologic findings for venous thrombosis were evaluated using computed tomography (CT) including scans of the axillary vein. Medical records were retrospectively reviewed. Results: The prevalence of symptomatic thrombosis was 0.38% (18/4,773). The patients with symptomatic venous thrombosis included 14 males and four females. Among the 18 patients, the most common types of cancer were lung cancer (n = 7) and pancreatic cancer (n = 4), with the incidence rates of 0.79% (lung cancer, 7/882) and 1.58% (pancreatic cancer, 4/253), respectively. The median time between placement of the TIVAP and diagnosis of thrombosis was 35.5 days (range: 6 - 292 days). All symptomatic patients had thrombosis in the axillary vein on CT images. Symptoms were improved in all patients with treatment including removal of TIVAP at the time of diagnosis and following anticoagulation therapy. From the multiple binary logistic regression, pancreatic cancer and lung cancer were statistically significant risk factors of symptomatic axillary vein thrombosis. Conclusion: After insertion of TIVAPs through the axillary vein, symptomatic axillary vein thrombosis rarely developed. Pancreatic cancer and lung cancer were associated with the risk of symptomatic axillary vein thrombosis.


1975 ◽  
Author(s):  
I. M. G. Macintyre ◽  
D. R. B. Jones ◽  
G. V. Ruckley

Venous thrombo-embolism has been considered to be rare in infancy and childhood. Hospital in-patient statistics in Scotland over a 4-year period were examined. Forty-nine patients aged 15 years or less had been coded as venous thrombosis. After computer and clinical errors had been removed 36 cases remained. Renal vein thrombosis accounted for 12 of these, caval thrombosis following ventriculo-atrial shunt 4, cerebral thrombophlebitis 3, umbilical vein thrombosis 2, pulmonary thrombosis in infancy 2, axillary vein thrombosis 2 and jugular venous thrombosis 1. There were 10 cases of deep vein thrombosis of the lower limb and a clinical study of these is the subject of this paper. Two patients also had pulmonary embolism and two others developed chronic venous insufficiency. Children at high risk are those with sepsis or trauma. Venous thrombosis may simulate osteomyelitis and pulmonary embolism may be misdiagnosed as bronchopneumonia. Clinicians must be aware of the possibility of thrombo-embolism in childhood if correct diagnosis and treatment is to be instituted.


BMJ ◽  
1935 ◽  
Vol 2 (3905) ◽  
pp. 895-895 ◽  
Author(s):  
A. D. Belilios ◽  
A. w. J. Houghton

1993 ◽  
Vol 41 (1) ◽  
pp. 120-120
Author(s):  
I Ben-Shlomo ◽  
G Azogui ◽  
A Prober ◽  
C Cozacov ◽  
S Zohar

Sign in / Sign up

Export Citation Format

Share Document